Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Novartis Venture Fund
Deal Size : $61.0 million
Deal Type : Series A Financing
Details : The financing will be used to advance a portfolio small-molecule drugs, including a clinical study in patients with Alzheimer's disease for the lead programme.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 10, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Novartis Venture Fund
Deal Size : $61.0 million
Deal Type : Series A Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery
Recipient : Concept Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The alliance will focus on identifying small molecule drugs able to modulate astrocyte biology to expand AstronauTx's pipeline of novel therapeutic candidates for the treatment of Alzheimer's disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 06, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery
Recipient : Concept Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration